44 citations
,
April 2006 in “Expert opinion on drug safety” Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
3 citations
,
August 2023 in “Journal of Cutaneous Medicine and Surgery” Topical Flutamide 1% gel effectively and safely reduces acne.
1 citations
,
July 2024 in “International Journal of Innovative Science and Research Technology (IJISRT)” Stopping steroids and providing supportive care improved the patient's Cushing Syndrome symptoms and ulcers.
October 2024 in “The Journal of Dermatology” Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
40 citations
,
October 2017 in “Acta Dermato Venereologica” Understanding patients' views on their illness can help improve their disease management.
1 citations
,
July 2025 in “Frontiers in Endocrinology” ApoBDs, once seen as waste, are now viewed as potential tools for disease treatment and tissue repair.
5 citations
,
January 2015 in “Skin appendage disorders” Colored hair-thickening fibers can help hide hair loss in some people with Epidermolysis Bullosa but may cause scalp irritation.
January 2026 in “DOAJ (DOAJ: Directory of Open Access Journals)” Early biopsy and targeting inflammation can improve treatment for hair loss in androgenetic alopecia.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
April 2017 in “Journal of Investigative Dermatology” SIG-1451 could be a promising new treatment for atopic dermatitis.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
10 citations
,
April 2013 in “Veterinary dermatology” A new skin disease in four Labrador retrievers responded well to immunosuppressive treatment.
26 citations
,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
September 2025 in “International Journal of Dermatology” February 2025 in “International Journal of Dermatology” August 2020 in “International Journal of Dermatology” January 2018 in “International Journal of Dermatology” November 2023 in “Journal of Investigative Dermatology” JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
November 2023 in “Gastroenterology” A woman with Budd-Chiari syndrome improved after treatment and needs a liver transplant, highlighting the importance of considering non-criteria antiphospholipid syndrome in similar cases.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
10 citations
,
May 2011 in “American Journal of Hematology” Vinblastine can help treat childhood ITP but may cause reversible side effects.
43 citations
,
January 2015 in “Journal of Cutaneous Medicine and Surgery” Most patients improved with oral antibiotics, but some needed long-term treatment or had minimal response.
November 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Certain medications and smaller pupil size increase the risk of intraoperative floppy iris syndrome during eye surgery.
January 2026 in “Dermatology and Therapy” UVFD can help doctors better identify harmful skin lesions on the face, reducing unnecessary biopsies.
January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.